Hormone replacement therapy and cancer risks in perimenopausal women: A retrospective cohort study using a Japanese claims database

AIM Hormone replacement therapy (HRT) relieves menopausal syndromes but concerns regarding certain cancer risks remain. This study aimed to investigate cancer risks in perimenopausal women using HRT. METHODS Using a health care database in Japan, we compared breast cancer and other cancer risks in perimenopausal women who started HRT between January 2011 and October 2021 at age 45-54 years with that of women who did not use HRT. Women in the control group were selected by 1:4 exact matching on birth year, and followed from the same index time as their counterparts. RESULTS Data from 12 207 women in the exposure group and 48 828 age-matched women in the control group were analyzed. The median HRT duration was 16.1 (interquartile range, 9.9-28.0) months. Breast cancer risk was lower in the HRT group (adjusted hazard ratio [HR], 0.67; 95% confidence interval [CI], 0.54-0.82). When stratified by age, breast cancer risk was lower in the HRT group who started HRT at age 45-49 years (adjusted HR, 0.54; 95% CI, 0.40-0.72). Estrogen-major HRT accounted for approximately one-third of HRT and uterine corpus cancer risk was increased in estrogen-major HRT (adjusted HR, 2.44; 95% CI, 1.56-3.81). CONCLUSIONS Breast cancer risk in women starting HRT between 45 and 49 years is lower than that in the average population; this finding might be susceptible to unmeasured factors such as early menopause among HRT recipients. Unopposed estrogen therapy accounts for considerable proportion of HRT in Japan and it increases uterine corpus cancer.

[1]  R. Lobo.  The 2022 hormone therapy position statement of The North American Menopause Society. , 2022, Menopause.

[2]  K. Yamaguchi,et al.  Acquired Evolution of Mitochondrial Metabolism Regulated by HNF1B in Ovarian Clear Cell Carcinoma , 2021, Cancers.

[3]  S. Kimura,et al.  Data resource profile: JMDC claims database sourced from health insurance societies , 2021, Journal of general and family medicine.

[4]  R. Langer,et al.  Hormone replacement therapy – where are we now? , 2021, Climacteric : the journal of the International Menopause Society.

[5]  T. Tabuchi,et al.  Trends in clinical stage distribution and screening detection of cancer in Osaka, Japan: Stomach, colorectum, lung, breast and cervix , 2020, PloS one.

[6]  G. Scambia,et al.  Hormone replacement therapy and cervical cancer: a systematic review of the literature , 2020, Climacteric : the journal of the International Menopause Society.

[7]  J. Hippisley-Cox,et al.  Use of hormone replacement therapy and risk of breast cancer: nested case-control studies using the QResearch and CPRD databases , 2020, BMJ.

[8]  J. Manson,et al.  Association of Menopausal Hormone Therapy With Breast Cancer Incidence and Mortality During Long-term Follow-up of the Women's Health Initiative Randomized Clinical Trials. , 2020, JAMA.

[9]  C. Cooper,et al.  Is there a role for menopausal hormone therapy in the management of postmenopausal osteoporosis? , 2020, Osteoporosis International.

[10]  Kyungdo Han,et al.  Hormone Replacement Therapy, Breast Cancer Risk Factors, and Breast Cancer Risk: A Nationwide Population-Based Cohort , 2020, Cancer Epidemiology, Biomarkers & Prevention.

[11]  J. Pinkerton.  Hormone Therapy for Postmenopausal Women. , 2020, The New England journal of medicine.

[12]  I. Lambrinoudaki,et al.  Breast cancer risk and hormone replacement therapy: Whether "absolute" or "relative", the conundrum remains. , 2019, European journal of obstetrics, gynecology, and reproductive biology.

[13]  L. Regan,et al.  HRT and breast cancer risk , 2019, BMJ.

[14]  V. Beral,et al.  Type and timing of menopausal hormone therapy and breast cancer risk: individual participant meta-analysis of the worldwide epidemiological evidence , 2019, The Lancet.

[15]  D. Longo,et al.  The Precision of Evidence Needed to Practice "Precision Medicine". , 2019, The New England journal of medicine.

[16]  T. Enomoto,et al.  Trends and characteristics of epithelial ovarian cancer in Japan between 2002 and 2015: A JSGO-JSOG joint study. , 2019, Gynecologic oncology.

[17]  I. Lambrinoudaki,et al.  Menopausal hormone therapy and breast cancer: Need to put risks in perspective. , 2019, Maturitas.

[18]  T. Kurabayashi,et al.  Japan Society of Obstetrics and Gynecology and Japan Society for Menopause and Women's Health 2017 guidelines for hormone replacement therapy , 2018, The journal of obstetrics and gynaecology research.

[19]  Wen Shi,et al.  Risk Factors and Preventions of Breast Cancer , 2017, International journal of biological sciences.

[20]  H. Adami,et al.  Menopausal hormone therapy and cancer risk: An overestimated risk? , 2017, European journal of cancer.

[21]  R. Lobo.  Hormone-replacement therapy: current thinking , 2017, Nature Reviews Endocrinology.

[22]  W. Mack,et al.  Back to the future: Hormone replacement therapy as part of a prevention strategy for women at the onset of menopause. , 2016, Atherosclerosis.

[23]  M. Lumsden,et al.  Diagnosis and Management of Menopause: The National Institute of Health and Care Excellence (NICE) Guideline. , 2016, JAMA internal medicine.

[24]  M. Rees,et al.  Revised global consensus statement on menopausal hormone therapy. , 2016, Maturitas.

[25]  Wendy J Mack,et al.  Vascular Effects of Early versus Late Postmenopausal Treatment with Estradiol. , 2016, The New England journal of medicine.

[26]  M. Paesmans,et al.  Menopausal hormone therapy use in relation to breast cancer incidence in 11 European countries. , 2016, Maturitas.

[27]  M. Murad,et al.  Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. , 2015, The Journal of clinical endocrinology and metabolism.

[28]  J. Manson,et al.  Management of Menopausal Symptoms. , 2015, Obstetrics and gynecology.

[29]  V. Beral,et al.  Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies , 2015, The Lancet.

[30]  Anne Eisinga,et al.  Hormone therapy for preventing cardiovascular disease in post-menopausal women. , 2015, The Cochrane database of systematic reviews.

[31]  M. Sammel,et al.  Risk of long-term hot flashes after natural menopause: evidence from the Penn Ovarian Aging Study cohort , 2014, Menopause.

[32]  J. Manson,et al.  Arterial imaging outcomes and cardiovascular risk factors in recently menopausal women: a randomized trial. , 2014, Annals of internal medicine.

[33]  P. Guénel,et al.  Risk of Breast Cancer by Type of Menopausal Hormone Therapy: a Case-Control Study among Post-Menopausal Women in France , 2013, PloS one.

[34]  E. Pukkala,et al.  Postmenopausal estradiol–progestagen therapy and risk for uterine cervical cancer , 2012, International journal of cancer.

[35]  Kunihiko Hayashi,et al.  Factors associated with premature ovarian failure, early menopause and earlier onset of menopause in Japanese women. , 2012, Maturitas.

[36]  M. Alan Brookhart,et al.  Healthy User and Related Biases in Observational Studies of Preventive Interventions: A Primer for Physicians , 2011, Journal of General Internal Medicine.

[37]  J. Manson,et al.  Postmenopausal hormone therapy: an Endocrine Society scientific statement. , 2010, The Journal of clinical endocrinology and metabolism.

[38]  E. Pukkala,et al.  Breast Cancer Risk in Postmenopausal Women Using Estradiol–Progestogen Therapy , 2009, Obstetrics and gynecology.

[39]  F. Clavel-Chapelon,et al.  Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study , 2007, Breast Cancer Research and Treatment.

[40]  A. Maclennan,et al.  Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. , 2004, The Cochrane database of systematic reviews.

[41]  R. Stafford,et al.  National use of postmenopausal hormone therapy: annual trends and response to recent evidence. , 2004, JAMA.

[42]  Charles Kooperberg,et al.  Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. , 2002, JAMA.